FDA Special Protocol Assessment
A Special Protocol Assessment (SPA) , is an advanced declaration from the Food and Drug Administration affecting the pharmaceutical industry and medical research. It pertains to an uncompleted Phase III trial's design, clinical endpoints, and statistical analyses that are acceptable for FDA approval. The purpose of a SPA is to allow a company to run or initiate a clinical trial of an experimental drug without fear that the FDA will object to the trial design itself, in the event that the company subsequently applies for product approval.[1]
Description[edit]
![[icon]](/File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. (January 2020) |
Three types of protocols related to PDUFA products are eligible for this special protocol assessment under the PDUFA goals:[2]
- animal carcinogenicity protocols,
- final product stability protocols,
- clinical protocols for phase 3 trials whose data will form the primary basis for an efficacy claim if the trials had been the subject of discussion at an end-of-phase 2/pre-phase 3 meeting with the review division, or in some cases, if the division agrees to such a review because the division is aware of the developmental context in which the protocol is being reviewed and the questions are being answered.
The clinical protocols for phase 3 trials can relate to efficacy claims that will be part of an original new drug application (NDA) or Biologic License Application (BLA) or that will be part of an efficacy supplement to an approved NDA or BLA.
References[edit]
 | This medical article is a stub. You can help EverybodyWiki by expanding it. |
This article "FDA Special Protocol Assessment" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:FDA Special Protocol Assessment. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
